What We Do

Dr. John C. Sharpe is the Chief Operating Officer of Cytonome. He has formerly held both CEO and CTO roles with the company since its formation in 2009. John has over two decades of experience in developing and commercializing advanced cellular analysis and sorting technologies and other biosensing platforms that utilize advanced biophysics principles. He is recognized in the flow cytometry industry as a key member of the (Cytomation, now Beckman Coulter) development team for the MoFlo high speed cell sorter, and as the program and technical lead on the CyAn high-performance analyzer system. John has led multiple product development and commercial initiatives in a range of companies and has been responsible for due diligence studies in a number of corporate acquisitions. He has and continues to serve on the Boards of several science and technology companies. John holds a Ph.D. from The University of Waikato, New Zealand.

Chris Canniff has thirty years of experience in organizations ranging from start-up companies to Fortune 100 corporations in the pharmaceutical, medical device, financial services, and commercial real estate industries.

Prior to joining Cytonome, Chris worked as a consultant, serving as an interim Chief Financial Officer or Controller for companies in transition. Some of Chris’ recent engagements include: Business Unit Controller for an international pharmaceutical company, CFO for a start-up medical device company, and Vice President of Finance for a national digital media firm.

Prior to consulting, Chris was the CFO of a private equity-backed service firm established to implement leveraged consolidation of companies that specialize in fundraising services for national and international non-profit organizations. Chris also held senior finance positions at Fleet Bank, First Data, and The Boston Company.  Chris began his career at Deloitte and Touché.